OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 03:35:40 2024-07-16 pm EDT | After market 03:59:19 pm | |||
| 2.34 EUR | -1.68% |
|
2.335 | -0.21% |
| Current month | +4.93% | ||
| 1 month | +0.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 2.34 | -1.68% |
| 24-07-15 | 2.38 | +1.71% |
| 24-07-12 | 2.34 | -1.27% |
| 24-07-11 | 2.37 | +0.42% |
| 24-07-10 | 2.36 | +1.29% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TT9R3L |
| ISIN | DE000TT9R3L7 |
| Date issued | 2021-12-03 |
| Strike | 235.3 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.41 € |
|---|---|
| Lowest since issue | 0.08 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
490.8
USD
Average target price
473.5
USD
Spread / Average Target
-3.54%
- Stock Market
- Certificates
- Certificat
